Ephedra seizure
This article was originally published in The Tan Sheet
Executive Summary
More than 2 mil. capsules of Asia MedLabs' ephedra-containing Vitera-XT were seized from the firm's facility in Houston by U.S. Marshals, FDA announces Nov. 23. Vitera-XT, a "traditional Asian formulation," lists ephedrine alkaloids among its ingredients and carries claims such as "treat[s]...persistent flu, fevers and [may be used] for protein release." The complaint the ingredients and claims render the product an "unapproved new and misbranded drug." FDA's final rule banning the botanical was published in February (1"The Tan Sheet" Feb. 9, 2004, p. 10)...
You may also be interested in...
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.